AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 24.04 |
|---|---|
| Change | -0.790 3.286% |
| 52 W H/L (in USD) | 16.190/4.500 |
| EBITDA (in USD) | -36.952M |
| PE Ratio | -- |
| Volume | 246452 |
| Diluted Eps TTM | -18.38 |
| Total Assets (in USD) | 46.08M |
|---|---|
| Total Liabilities (in USD) | 8.145M |
| Revenue TTM (in USD) | 12.5M |
| Cash (in USD) | 36.043M |
| Market Cap (in USD) | 33.363 M |
| Revenue Per Share TTM | 6.017 |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Surrozen Inc
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
650 489 9000
Employees: 42
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Craig C. Parker M.B.A. | CEO, Pres & Director | 1962 |
| 2. | Mr. Charles Williams | Chief Financial Officer | 1980 |
| 3. | Dr. Wen-Chen Yeh M.D., Ph.D. | Chief Scientific Officer | 1964 |
| 4. | Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisor | NA |
| 5. | Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisor | 1950 |
| 6. | Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor | NA |
| 7. | Ms. Sheela Mohan-Peterson J.D., M.S. | Sr. VP of Legal, Gen. Counsel & Corp. Sec. | 1962 |
| 8. | Dr. Geertrui Vanhove M.B.A., M.D., Ph.D. | Chief Medical Officer | 1966 |
| 9. | Dr. Li Yang Ph.D. | Sr. VP of Biology | NA |
| 10. | Ms. Elizabeth Nguyen | Sr. VP and Head of Talent & Culture | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -36.004M | -54.648M | -32.716M | - |
| Minority Interest | - | - | - | - |
| Net Income | -27.669M | -52.51M | -32.625M | - |
| Selling General Administrative | 19.826M | 14.214M | 7.123M | - |
| Gross Profit | 12.5M | - | - | - |
| Reconciled Depreciation | 1.955M | 2.066M | 1.937M | - |
| Ebit | -46.294M | -56.457M | -32.807M | -25.106M |
| Ebitda | -44.339M | -54.391M | -30.87M | - |
| Depreciation And Amortization | 1.955M | 2.066M | 1.937M | - |
| Operating Income | -44.339M | -54.391M | -32.807M | - |
| Other Operating Expenses | 56.839M | 54.391M | 32.807M | - |
| Interest Expense | 1.955M | 2.066M | 0.091M | 0M |
| Tax Provision | - | - | - | - |
| Interest Income | 0.781M | 0.072M | 0.091M | - |
| Net Interest Income | 0.781M | 0.072M | 0.091M | - |
| Income Tax Expense | -8.335M | -2.138M | -0.091M | - |
| Total Revenue | 12.5M | 0M | 0M | - |
| Total Operating Expenses | 56.839M | 54.391M | 32.807M | - |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 8.335M | -0.257M | 0.091M | - |
| Net Income From Continuing Ops | -36.004M | -54.648M | -32.716M | - |
| Net Income Applicable To Common Shares | - | -54.648M | -32.716M | -24.362M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 46.08M | 89.435M | 137.174M | 62.06M | - |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.937M | 3.489M | 3.338M | 1.042M | - |
| Total Liab | 8.145M | 13.434M | 27.474M | 14.767M | - |
| Total Stockholder Equity | 37.935M | 76.001M | 109.7M | 47.293M | - |
| Other Current Liab | 4.126M | 6.848M | 0.589M | 0.416M | - |
| Common Stock | - | 0.003M | 0.004M | 0.002M | 0.001M |
| Capital Stock | 0M | 0.003M | 0.004M | 0.002M | - |
| Retained Earnings | -221.695M | -178.653M | -142.649M | -88.001M | -55.285M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0.954M | 0.444M | 0.454M |
| Cash | 36.043M | 24.69M | 33.091M | 34.982M | - |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 7.148M | 9.732M | 13.573M | 7.278M | 3.9M |
| Current Deferred Revenue | - | - | 8.073M | 2.978M | - |
| Net Debt | -32.664M | -19.088M | -25.298M | -25.385M | - |
| Short Term Debt | 2.497M | 2.226M | 2.193M | 2.108M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 3.379M | 5.602M | 7.793M | 9.597M | - |
| Other Stockholder Equity | 259.63M | 254.892M | 252.464M | 135.292M | - |
| Property Plant Equipment | - | - | 9.376M | 11.392M | 12.617M |
| Total Current Assets | 41.132M | 81.305M | 105.189M | 50.224M | 29.414M |
| Long Term Investments | - | 0M | 21.655M | 0M | - |
| Short Term Investments | 0M | 51.148M | 68.76M | 14.2M | - |
| Net Receivables | 2.152M | 1.978M | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | 0M | - | - | - | - |
| Accounts Payable | 0.525M | 0.658M | 2.718M | 1.776M | 0.972M |
| Accumulated Other Comprehensive Income | - | -0.241M | -0.119M | - | - |
| Non Currrent Assets Other | 0.402M | 1.232M | 0.954M | 0.444M | - |
| Non Current Assets Total | 4.948M | 8.13M | 31.985M | 11.836M | - |
| Capital Lease Obligations | 3.379M | 5.602M | 7.793M | 9.597M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | 38.309M | -77.708M | -14.201M | -14.201M |
| Total Cashflows From Investing Activities | - | -77.708M | -15.075M | -1.563M |
| Total Cash From Financing Activities | -2.565M | 124.63M | 50.052M | 28.904M |
| Net Income | -36.004M | -54.648M | -32.716M | -24.362M |
| Change In Cash | -8.401M | -1.891M | 5.878M | 6.285M |
| Begin Period Cash Flow | 33.496M | 35.387M | 29.509M | - |
| End Period Cash Flow | 25.095M | 33.496M | 35.387M | 29.509M |
| Total Cash From Operating Activities | -44.145M | -48.813M | -29.099M | -21.056M |
| Depreciation | 1.955M | 2.066M | 1.937M | 2.283M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | -2.607M | - | - | - |
| Other Cashflows From Financing Activities | 0.042M | 0.41M | -15.075M | - |
| Capital Expenditures | 0.728M | 1.269M | 0.874M | 1.563M |
| Change In Working Capital | -8.418M | -0.221M | 0.052M | - |
| Other Non Cash Items | -6.195M | 1.231M | 0.992M | - |
| Free Cash Flow | -44.873M | -50.082M | -29.973M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 42278 |
| 2. | BlackRock Extended Mkt Composite | 2 years ago | 36199 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 18127 |
| 4. | Fidelity Extended Market Index | 2 years ago | 6573 |
| 5. | BlackRock Extended Equity Market K | 2 years ago | 2105 |
| 6. | Fidelity Series Total Market Index | 2 years ago | 1401 |
| 7. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 1208 |
| 8. | Spartan Total Market Index Pool E | 2 years ago | 1208 |
| 9. | Dimensional US Core Equity 1 ETF | 2 years ago | 1205 |
| 10. | Fidelity Nasdaq Composite Index | 2 years ago | 1130 |
| 11. | Northern Trust Extended Eq Market Idx | 2 years ago | 1009 |
| 12. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 1009 |
| 13. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 970 |
| 14. | Fidelity Total Market Index | 2 years ago | 780 |
| 15. | Vanguard Instl Ttl Stck Mkt Idx Tr | 2 years ago | 676 |
| 16. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 2 years ago | 665 |
| 17. | SSgA U.S. Extended Market Index Class I | 2 years ago | 606 |
| 18. | State St US Extended Mkt Indx NL Cl C | 2 years ago | 606 |
| 19. | Vanguard U.S. Eq Idx £ Acc | 2 years ago | 430 |
| 20. | BNYM Mellon SL Market Completion UC1 | 2 years ago | 411 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Column Group LLC | 2 years ago | 627651 |
| 2. | Euclidean Capital LLC | 2 years ago | 87696 |
| 3. | Vanguard Group Inc | 2 years ago | 61511 |
| 4. | BlackRock Inc | 2 years ago | 58494 |
| 5. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 2 years ago | 55123 |
| 6. | Board of Ttees Leland Stanford Jr Univ | 2 years ago | 52131 |
| 7. | Trustees Of Columbia University In The City Of New York | 2 years ago | 47930 |
| 8. | Morgan Stanley - Brokerage Accounts | 2 years ago | 35211 |
| 9. | Geode Capital Management, LLC | 2 years ago | 11473 |
| 10. | Renaissance Technologies Corp | 2 years ago | 10326 |
| 11. | Tower Research Capital LLC | 2 years ago | 612 |
| 12. | Wolverine Asset Management LLC | 2 years ago | 281 |
| 13. | Royal Bank of Canada | 2 years ago | 111 |
| 14. | UBS Group AG | 2 years ago | 46 |
| 15. | Wells Fargo & Co | 2 years ago | 9 |
| 16. | JPMorgan Chase & Co | 2 years ago | 3 |
| 17. | State Street Corporation | 2 years ago | 0 |
| 18. | Prudential Financial Inc | 2 years ago | 0 |
| 19. | Northern Trust Corp | 2 years ago | 0 |
| 20. | Harvard Management Co Inc | 2 years ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...